The vast majority of ALL patients present a constitutive activation of the canonical NF-κB pathway in the form of RelA/p50 complexes, which is an important switch to ensure the survival of ALL cells by blocking apoptosis or enhancing cell proliferation [21]. This evidence concerns the gene CD40 and acute lymphoblastic leukemia.